title: Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain?
abstract: Rosiglitazone often results in weight gain. We hypothesized that rosiglitazone may modulate circulating levels of ghrelin and peptide YY(3-36) and this modulation may be related to weight-gaining effect of this agent. This study was designed as an open-label, randomized, controlled trial of 3-month duration. Women with newly diagnosed type 2 diabetes were studied. Twenty-eight of the 55 eligible participants were randomly assigned to receive rosiglitazone (4 mg/d). Twenty-seven patients with diabetes matched for age and body mass index served as controls on diet alone. We evaluated the effects of 3 months of rosiglitazone treatment on fasting peptide YY(3-36) and ghrelin levels, and anthropometric measurements. The 3-month administration of rosiglitazone reduced fasting plasma peptide YY(3-36) levels by 25%, the between-group difference was statistically significant. No effect of this thiazolidinedione compound on fasting ghrelin concentrations was observed at the end of study. The ghrelin/body mass index ratio also did not change significantly after treatment. Seventy-five percent of the women with diabetes complained of increased hunger at the end of study. Nevertheless, all subjects exhibited a decrease in fasting PYY levels after 3 months of rosiglitazone therapy, irrespective of the levels of hunger. There was no significant correlation between changes in peptide YY(3-36) and those in anthropometric parameters and insulin sensitivity at the end of the study. Rosiglitazone-induced decrease in fasting peptide YY(3-36) levels may in part contribute to orexigenic and weight-gaining effect of this thiazolidinedione derivative.
authors.affiliation: Department of Endocrinology and Metabolism, Turkiye Yuksek Ihtisas Education and Research Hospital, Kızılay sokak, 06100 Sihhiye, Ankara, Turkey. zehraberberoglu@gmail.com
authors.forename: Zehra
authors.initials: Z
authors.lastname: Berberoglu
authors.forename: Ayse Canan
authors.initials: AC
authors.lastname: Yazici
authors.forename: Nilufer
authors.initials: N
authors.lastname: Bayraktar
authors.forename: Nilgun Guvener
authors.initials: NG
authors.lastname: Demirag
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D015536:Down-Regulation / Q000187:drug effects; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D019894:Peptide YY / Q000097:blood*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D045162:Thiazolidinediones; D000077154:Rosiglitazone; D019894:Peptide YY